BVS
Bioventus Inc.
BVS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over BVS overall, supported by stronger fundamentals and lower modeled downside.
BVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
BVS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BVS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $10.86 | — |
| Current | 14x | $10.86 | — |
| Cheap | 18x | $14.37 | +32% |
| Fair | 26x | $21.13 | +95% |
| Expensive | 69x | $54.91 | +406% |
Historical ranges are pointers, not guarantees.
BVS has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BVS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for BVS, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BVS on the outlook, with more favorable valuation expectations.
BVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +1.6% |
| Q3 2026 | $0.80 | +627% |
| Q2 2026 | $0.77 | +$0.78 |
| Q1 2026 | $0.41 | +$0.90 |
| Q4 2025 | $0.33 | +$0.85 |
| Q3 2025 | $0.11 | +$0.69 |
| Q2 2025 | -$0.01 | +$0.62 |
| Q1 2025 | -$0.49 | -$0.17 |
| Q4 2024 | -$0.52 | +$1.97 |
BVS's earnings per share have jumped to their highest in five years: $0.80 over the past year, up from $0.11 the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BVS on earnings, with more consistent year-over-year improvement.
BVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $142.4M | +2.7% |
| Q2 2026 | $153.2M | +3.8% |
| Q1 2026 | $132.1M | +6.6% |
| Q4 2025 | $157.9M | +2.8% |
| Q3 2025 | $138.7M | -0.2% |
| Q2 2025 | $147.7M | -2.4% |
| Q1 2025 | $123.9M | -4.3% |
| Q4 2024 | $153.6M | +13% |
BVS's revenue grew through 2024 and has held roughly level since: $142M last quarter, up 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | -1.3 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | 6.4% | +2.4 points |
| Q4 2025 | 12% | +7.1 points |
| Q3 2025 | 8.1% | +5.2 points |
| Q2 2025 | 12% | +32 points |
| Q1 2025 | 3.9% | -0.2 points |
| Q4 2024 | 5.2% | +4.3 points |
BVS's operating margin was 6.8% last quarter, down 1.3 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BVS on profitability, with a higher operating margin.
BVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.3M | -31% |
| Q2 2026 | $18.9M | -25% |
| Q1 2026 | $8.4M | +$28.5M |
| Q4 2025 | $37.4M | +99% |
| Q3 2025 | $29.6M | +189% |
| Q2 2025 | $25.3M | +67% |
| Q1 2025 | -$20.2M | -$13.9M |
| Q4 2024 | $18.7M | +87% |
BVS generated $85M in free cash flow over the past year, up 59% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BVS on cash flow, with more consistent year-over-year improvement.
BVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +1.7M shares |
| 1 year | +5.3% | +3.7M shares |
| 3 years | +15% | +9.7M shares |
| 5 years | +73% | +30.7M shares |
| Available history | +30% | +16.9M shares |
BVS has 72M diluted shares, up 5.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BVS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 4.9x | High |
| Q1 2025 | 20.2x | High |
| Q4 2024 | 18.0x | High |
BVS's net debt is about 2.4 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BVS on leverage, with a lower net debt burden relative to earnings.
BVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
BVS's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BVS PE vs Healthcare Sector
| Metric | BVS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 2 | 35 | 33 pts below |
BVS has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 16% below |
| 20 week MA | $13.0 | 16% below |
| 50 week MA | $10.4 | 4.4% above |
| 100 week MA | $9.16 | 19% above |
| 200 week MA | $7.20 | 51% above |
BVS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 51% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BVS on trend strength, trading above more of its moving averages.
BVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.2 | $14.0 | -19% |
| 2022 | $14.0 | $2.54 | -82% |
| 2023 | $2.54 | $5.27 | +107% |
| 2024 | $5.27 | $10.6 | +102% |
| 2025 | $10.6 | $7.46 | -30% |
| 2026 YTD | $7.46 | $10.9 | +46% |
BVS has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.